[Federal Register: January 23, 2002 (Volume 67, Number 15)]
[Notices]
[Page 3219]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23ja02-83]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Vaccines and Related Biological Products
Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on January 30, 2002, from 9
a.m. to 5 p.m.
Location: Holiday Inn, Versailles I and II, 8120 Wisconsin Ave.,
Bethesda, MD.
Contact: William Freas or Denise H. Royster, Center for Biologics
Evaluation and Research (HFM-71), Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 12391. Please call the Information Line for
up-to-date information on this meeting.
Agenda: On January 30, 2002, the committee will discuss the
influenza virus vaccine formulation for the 2002-2003 season.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by January 22,
2002. Oral presentations from the public will be scheduled between
approximately 9:30 a.m. and 9:45 a.m., and approximately 4:15 p.m. and
5 p.m. Time allotted for each presentation may be limited. Those
desiring to make formal oral presentations should notify the contact
person before January 22, 2002, and submit a brief statement of the
general nature of the evidence or arguments they wish to present, the
names and addresses of proposed participants, and an indication of the
approximate time requested to make their presentation.
FDA regrets that it was unable to publish this notice 15 days prior
to the Vaccines and Related Biological Products Advisory Committee
meeting. Because the agency believes there is some urgency to bring
this issue to public discussion and qualified members of the Vaccines
and Related Biological Products Advisory Committee were available at
this time, the Commissioner of Food and Drugs concluded that it was in
the public interest to hold this meeting even if there was not
sufficient time for the customary 15-day public notice.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: January 17, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 02-1713 Filed 1-18-02; 1:52 pm]
BILLING CODE 4160-01-S